Status:
UNKNOWN
Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
National Cheng-Kung University Hospital
Taichung Veterans General Hospital
Conditions:
Hepatocellular Carcinoma Non-resectable
Chemoembolization, Therapeutic
Eligibility:
All Genders
Brief Summary
To evaluate efficacy and safety profile of DC bead® TACE in patients with hepatocellular carcinoma in Taiwan.
Detailed Description
To evaluate efficacy and safety profile of DC bead TACE in patients with hepatocellular carcinoma in Taiwan. This is a multi-center, retrospective, single arm study to explore safety and efficacy of ...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of HCC, according to the AASLD diagnosis criteria for HCC.
- Patient received DC bead TACE.
Exclusion
- Patients with current any other cancer except non-melanomatous skin cancer.
- Infiltrative HCC
- Patients received ≥2 consecutive sessions of TACE (≥2 TACE at the same admission, no matter it is cTACE or DC bead TACE)
- Patients received DC bead TACE and simultaneously received other therapy, such as radiotherapy, sorafenib etc.
- Presence of collateral vessel pathways potentially endangering normal territories during embolization.
- Presence of arteries supplying the lesion not large enough to accept DC Bead® microspheres.
Key Trial Info
Start Date :
September 13 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2018
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT03283956
Start Date
September 13 2017
End Date
August 31 2018
Last Update
September 15 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan